$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2023 Q3 Form 10-Q Financial Statement

#000141057823001633 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $406.0K $201.0K $477.0K
YoY Change 97.09% -57.86% 14.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.030M $7.564M $7.931M
YoY Change -13.53% -4.63% 7.58%
% of Gross Profit
Research & Development $7.201M $6.214M $13.65M
YoY Change -6.41% -54.46% 150.32%
% of Gross Profit
Depreciation & Amortization $410.0K $350.0K $524.0K
YoY Change 32.26% -33.21% 580.52%
% of Gross Profit
Operating Expenses $7.201M $6.214M $21.58M
YoY Change -6.41% -71.2% 295.82%
Operating Profit -$13.83M -$13.58M -$21.10M
YoY Change -11.48% -35.65% 70.06%
Interest Expense $1.670M $1.302M -$8.459M
YoY Change 10.45% -115.39% -1148.2%
% of Operating Profit
Other Income/Expense, Net -$4.755M -$871.0K -$8.569M
YoY Change -72.41% -89.84% -150.95%
Pretax Income -$18.58M -$14.45M -$29.67M
YoY Change -43.44% -51.3% -772.74%
Income Tax
% Of Pretax Income
Net Earnings -$18.58M -$14.45M -$29.67M
YoY Change -43.44% -51.3% -772.74%
Net Earnings / Revenue -4576.35% -7188.06% -6219.71%
Basic Earnings Per Share -$0.02 -$0.01 -$0.01
Diluted Earnings Per Share -$0.02 -$0.01 -$29.55K
COMMON SHARES
Basic Shares Outstanding 1.121B 1.087B 984.2M
Diluted Shares Outstanding 1.134M 1.108M 1.004M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.100M $1.424M $4.831M
YoY Change -35.28% -70.52% 28.55%
Cash & Equivalents $6.097M $1.424M $4.831M
Short-Term Investments
Other Short-Term Assets $1.750M $3.218M $2.347M
YoY Change -25.18% 37.11% -48.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.452M $4.642M $7.178M
YoY Change -28.15% -35.33% -14.03%
LONG-TERM ASSETS
Property, Plant & Equipment $16.75M $17.29M $18.08M
YoY Change 27.62% -4.41% 1278.28%
Goodwill $626.0K $626.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $357.0K $361.0K $342.0K
YoY Change 5.31% 5.56% -68.71%
Total Long-Term Assets $23.04M $23.80M $20.34M
YoY Change 19.17% 16.97% -0.37%
TOTAL ASSETS
Total Short-Term Assets $8.452M $4.642M $7.178M
Total Long-Term Assets $23.04M $23.80M $20.34M
Total Assets $31.49M $28.44M $27.52M
YoY Change 1.27% 3.33% -4.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.05M $18.66M $14.03M
YoY Change 22.09% 33.01% 23.64%
Accrued Expenses $370.0K $385.0K $329.0K
YoY Change 10.78% 17.02% 32.13%
Deferred Revenue
YoY Change
Short-Term Debt $3.450M $1.858M $0.00
YoY Change
Long-Term Debt Due $18.45M $8.403M $9.993M
YoY Change -8.51% -15.91% 30.54%
Total Short-Term Liabilities $49.22M $39.93M $98.16M
YoY Change -57.61% -59.33% -72.79%
LONG-TERM LIABILITIES
Long-Term Debt $11.04M $15.74M $16.45M
YoY Change 85.8% -4.33% 32.76%
Other Long-Term Liabilities $8.680M $8.419M $4.574M
YoY Change 110.07% 84.06% -16.93%
Total Long-Term Liabilities $19.72M $24.16M $21.03M
YoY Change 95.77% 14.9% 17.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.22M $39.93M $98.16M
Total Long-Term Liabilities $19.72M $24.16M $21.03M
Total Liabilities $68.95M $64.09M $119.2M
YoY Change -45.37% -46.23% -68.52%
SHAREHOLDERS EQUITY
Retained Earnings -$1.341B -$1.322B
YoY Change 5.67%
Common Stock $1.272B $1.259B
YoY Change 10.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$65.12M -$61.03M -$91.67M
YoY Change
Total Liabilities & Shareholders Equity $31.49M $28.44M $27.52M
YoY Change 1.27% 3.33% -4.33%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$18.58M -$14.45M -$29.67M
YoY Change -43.44% -51.3% -772.74%
Depreciation, Depletion And Amortization $410.0K $350.0K $524.0K
YoY Change 32.26% -33.21% 580.52%
Cash From Operating Activities -$13.92M -$11.52M -$14.84M
YoY Change -13.64% -22.37% 118.51%
INVESTING ACTIVITIES
Capital Expenditures $440.0K $1.249M -$408.0K
YoY Change -259.42% -406.13% -72.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$440.0K -$1.249M -$408.0K
YoY Change 59.42% 206.13% -72.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.12M 8.638M 10.41M
YoY Change 5.12% -17.03% 117.76%
NET CHANGE
Cash From Operating Activities -13.92M -11.52M -14.84M
Cash From Investing Activities -440.0K -1.249M -408.0K
Cash From Financing Activities 17.12M 8.638M 10.41M
Net Change In Cash 2.760M -4.132M -4.838M
YoY Change -2655.56% -14.59% 37.52%
FREE CASH FLOW
Cash From Operating Activities -$13.92M -$11.52M -$14.84M
Capital Expenditures $440.0K $1.249M -$408.0K
Free Cash Flow -$14.36M -$12.77M -$14.43M
YoY Change -9.35% -11.52% 173.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001072379
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Security Exchange Name
SecurityExchangeName
NONE
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1068400000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1115200000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35737
dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
497-9024
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NWBO
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1121070972
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1121070972
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1424000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6965000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3218000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2460000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
4642000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9425000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17286000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
CY2022Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
2028000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4231000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4189000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2023Q2 us-gaap Goodwill
Goodwill
626000
CY2022Q4 us-gaap Goodwill
Goodwill
626000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
361000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
345000
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
23796000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21898000
CY2023Q2 us-gaap Assets
Assets
28438000
CY2022Q4 us-gaap Assets
Assets
31323000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12107000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10687000
CY2023Q2 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
6551000
CY2022Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
6955000
CY2023Q2 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
1858000
CY2022Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
8403000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
15403000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8706000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8668000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1083000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2023Q2 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
609000
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2566000
CY2023Q2 nwbo Share Liability
ShareLiability
223000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
385000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
354000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
39925000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126005000
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
15743000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5991000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4369000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4370000
CY2023Q2 nwbo Contingent Payment Obligation Noncurrent
ContingentPaymentObligationNoncurrent
4050000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
24162000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10361000
CY2023Q2 us-gaap Liabilities
Liabilities
64087000
CY2022Q4 us-gaap Liabilities
Liabilities
136366000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1115200000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1068400000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1115000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1068000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1258259000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1164885000
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2022Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1322222000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1297122000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1893000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3145000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61034000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28438000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31323000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
201000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
477000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1081000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
880000
CY2023Q2 us-gaap Revenues
Revenues
201000
CY2022Q2 us-gaap Revenues
Revenues
477000
us-gaap Revenues
Revenues
1081000
us-gaap Revenues
Revenues
880000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6214000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13645000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13075000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18465000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7564000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7931000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14547000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15800000
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
13778000
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21576000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
27622000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
34265000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13577000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21099000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26541000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33385000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
107000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4254000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3987000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3714000
CY2023Q2 nwbo Fair Value Adjustment Of Share Liability
FairValueAdjustmentOfShareLiability
99000
nwbo Fair Value Adjustment Of Share Liability
FairValueAdjustmentOfShareLiability
47000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-472000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-110000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1880000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
300000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1302000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1432000
us-gaap Interest Expense
InterestExpense
2329000
us-gaap Interest Expense
InterestExpense
3335000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
697000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-2773000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1616000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3748000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-871000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8569000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1441000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10497000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14448000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29668000
us-gaap Net Income Loss
NetIncomeLoss
-25100000
us-gaap Net Income Loss
NetIncomeLoss
-43882000
CY2023Q2 nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
519000
nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
914000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14967000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29668000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26014000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43882000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
502000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-2375000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
1252000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-3183000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15469000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27293000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27266000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40699000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1108420
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1003976
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1091754
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
981737
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1108420
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1003976
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1091754
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
981737
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-55978000
CY2023Q2 nwbo Temporary Equity Stock Issued During Period Value Common Stock Warrant Exercise
TemporaryEquityStockIssuedDuringPeriodValueCommonStockWarrantExercise
945000
CY2023Q2 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
2521000
CY2023Q2 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
3948000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190000
CY2023Q2 nwbo Adjustments To Additional Paid In Capital Reclass Issued Milestone Shares From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassIssuedMilestoneSharesFromLiabilityToEquity
2130000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14448000
CY2023Q2 nwbo Adjustments To Additional Paid In Capital Warrants Modification
AdjustmentsToAdditionalPaidInCapitalWarrantsModification
679000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
519000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-502000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61034000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-120525000
CY2022Q2 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
6325000
CY2022Q2 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
5371000
CY2022Q2 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
11973000
CY2022Q2 nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise
25375000
CY2022Q2 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
1345000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5763000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29668000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2375000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-91666000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
nwbo Temporary Equity Stock Issued During Period Value Common Stock Warrant Exercise
TemporaryEquityStockIssuedDuringPeriodValueCommonStockWarrantExercise
3562000
nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
2769000
nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities To Stockholders Deficit
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToStockholdersDeficit
76258000
nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
9564000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1108000
us-gaap Net Income Loss
NetIncomeLoss
-25100000
nwbo Adjustments To Additional Paid In Capital Warrants Modification
AdjustmentsToAdditionalPaidInCapitalWarrantsModification
1074000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
914000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1252000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61034000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-123991000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9689000
nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
9556000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
19688000
nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
25379000
CY2022 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
2332000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6380000
us-gaap Net Income Loss
NetIncomeLoss
-43882000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3183000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-91666000
us-gaap Net Income Loss
NetIncomeLoss
-25100000
us-gaap Net Income Loss
NetIncomeLoss
-43882000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
685000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
624000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1276000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1509000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3987000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3714000
nwbo Fair Value Adjustment Of Share Liability
FairValueAdjustmentOfShareLiability
47000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1880000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
300000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
138000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1211000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
6380000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1156000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
12048000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
681000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
286000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
14000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
-660000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2206000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1533000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-404000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
2056000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
77000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
63000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22760000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27808000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
2582000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
466000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2582000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-466000
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
9465000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1566000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9556000
nwbo Proceeds From Investor Advance
ProceedsFromInvestorAdvance
7000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
600000
nwbo Proceeds From Issuance Of Convertible Notes Payable
ProceedsFromIssuanceOfConvertibleNotesPayable
1149000
nwbo Proceeds From Contingent Payment Obligation
ProceedsFromContingentPaymentObligation
4050000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
208000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5290000
nwbo Repayment Of Investor Advances
RepaymentOfInvestorAdvances
100000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21220000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14331000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1419000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3605000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5541000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10338000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6965000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15169000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1424000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4831000
nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
10000
nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
29000
nwbo Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash
ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash
19688000
nwbo Reclassification Of Warrant Liabilities To Stockholders Deficit Non Cash Investing And Financing Activities
ReclassificationOfWarrantLiabilitiesToStockholdersDeficitNonCashInvestingAndFinancingActivities
76258000
nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
25379000
nwbo Reclassification Of Investor Advances To Convertible Notes Payable
ReclassificationOfInvestorAdvancesToConvertibleNotesPayable
661000
nwbo Reclassification Of Investor Advances To Stockholders Deficit
ReclassificationOfInvestorAdvancesToStockholdersDeficit
1203000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
9564000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
2229000
nwbo Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption
IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption
1013000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3562000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
266000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
49000
nwbo Reclassification Between Shares Payable And Equity
ReclassificationBetweenSharesPayableAndEquity
250000
nwbo Deemed Dividend Related To Warrant Modification Non Cash Investing And Financing Activities
DeemedDividendRelatedToWarrantModificationNonCashInvestingAndFinancingActivities
914000
us-gaap Net Income Loss
NetIncomeLoss
-25100000
us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
22800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets, and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.</span></p>
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
90712000
nwbo Fair Value Liabilities Transfer Between Levels Amount
FairValueLiabilitiesTransferBetweenLevelsAmount
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 nwbo Number Of Warrants To Purchase Shares Of Common Stock Reclassified From Liability To Equity
NumberOfWarrantsToPurchaseSharesOfCommonStockReclassifiedFromLiabilityToEquity
141000000
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q2 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1100000
nwbo Modification Of Equity Classified Warrants
ModificationOfEquityClassifiedWarrants
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Modification of Equity Classified Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.</p>
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1083000
CY2023Q2 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8706000
CY2023Q2 nwbo Share Liability
ShareLiability
223000
CY2023Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
10012000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2022Q4 nwbo Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability
807000
CY2022Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8668000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
90712000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
663000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption
-1071000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
76258000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-4034000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10012000
CY2023Q2 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1100000
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2300000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
277000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5763000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1211000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6380000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
301263000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
135225000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1827000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.41
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
299436000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
73083000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
281278000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
69223000
nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17286000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
us-gaap Depreciation
Depreciation
700000
us-gaap Depreciation
Depreciation
600000
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
27715000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1711000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
26004000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
22454000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1732000
CY2022Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
807000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21529000
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
1100000
nwbo Accrued Share Liabilities
AccruedShareLiabilities
700000
us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
1800000
CY2023Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
800000
CY2022Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
1400000
CY2022Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
700000
us-gaap Interest And Debt Expense
InterestAndDebtExpense
2300000
us-gaap Interest And Debt Expense
InterestAndDebtExpense
3300000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1300000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
459685000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
462698000
nwbo Percentage Of Margin
PercentageOfMargin
0.15
nwbo Ancillary Services Agreement Additional Term Of Agreement
AncillaryServicesAgreementAdditionalTermOfAgreement
P12M
nwbo Payment Of Milestones In Cash
PaymentOfMilestonesInCash
2000000.0
nwbo Amount Recognized And Expensed Related To Current Cash Component
AmountRecognizedAndExpensedRelatedToCurrentCashComponent
1000000.0
nwbo Number Of Milestones Completed
NumberOfMilestonesCompleted
2
nwbo Partial Payment For Milestone Completed
PartialPaymentForMilestoneCompleted
1000000.0
nwbo Shares Issued For Completion Of Milestone
SharesIssuedForCompletionOfMilestone
3.0
CY2023Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
2100000
nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
500000
CY2022 nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
1600000
CY2023Q2 nwbo Amount Recognized And Expensed Not Yet Paid
AmountRecognizedAndExpensedNotYetPaid
500000
nwbo Amount Related To Future Cash Milestone Payments Anticipated To Achieve And Earn
AmountRelatedToFutureCashMilestonePaymentsAnticipatedToAchieveAndEarn
200000
nwbo Fair Value Of Future Shares Milestone Payments Anticipate To Achieve And Earn
FairValueOfFutureSharesMilestonePaymentsAnticipateToAchieveAndEarn
100000
CY2023Q2 nwbo Related Party Transaction Research And Development Costs From Transactions With Related Party Settled In Cash
RelatedPartyTransactionResearchAndDevelopmentCostsFromTransactionsWithRelatedPartySettledInCash
60000
CY2022Q2 nwbo Related Party Transaction Research And Development Costs From Transactions With Related Party Settled In Cash
RelatedPartyTransactionResearchAndDevelopmentCostsFromTransactionsWithRelatedPartySettledInCash
2314000
nwbo Related Party Transaction Research And Development Costs From Transactions With Related Party Settled In Cash
RelatedPartyTransactionResearchAndDevelopmentCostsFromTransactionsWithRelatedPartySettledInCash
210000
nwbo Related Party Transaction Research And Development Costs From Transactions With Related Party Settled In Cash
RelatedPartyTransactionResearchAndDevelopmentCostsFromTransactionsWithRelatedPartySettledInCash
2314000
CY2023Q2 us-gaap Area Of Land
AreaOfLand
88000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
36000
us-gaap Sublease Income
SubleaseIncome
72000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
nwbo Proceeds From Outstanding Warrant Exercises Including Investor Advances
ProceedsFromOutstandingWarrantExercisesIncludingInvestorAdvances
2800000
CY2022 nwbo Proceeds From Investor Advances
ProceedsFromInvestorAdvances
1200000
nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
12300000
nwbo Number Of Options Cash Less Exercise
NumberOfOptionsCashLessExercise
1500000
nwbo Debt Instrument Redemption Shares Issued
DebtInstrumentRedemptionSharesIssued
15200000
nwbo Debt Instrument Redemption Amount
DebtInstrumentRedemptionAmount
7400000
nwbo Debt Instrument Redemption Amount Interest
DebtInstrumentRedemptionAmountInterest
700000
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
1100000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
141048
CY2022Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.31
CY2022 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y1M28D
nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
12320
nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.22
nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
10615
nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.20
nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
250
nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
1.36
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
117863
CY2023Q2 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.31
nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y8M19D
nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
98000000
nwbo Share Based Payment Arrangement Plan Modification Associated With Debt Financing As Additional Debt Discount
ShareBasedPaymentArrangementPlanModificationAssociatedWithDebtFinancingAsAdditionalDebtDiscount
200000
nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
900000
CY2023Q2 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4800000
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4200000
us-gaap Operating Lease Cost
OperatingLeaseCost
417000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
49000
us-gaap Variable Lease Cost
VariableLeaseCost
7000
us-gaap Sublease Income
SubleaseIncome
72000
us-gaap Lease Cost
LeaseCost
401000
us-gaap Operating Lease Payments
OperatingLeasePayments
457000
us-gaap Operating Lease Cost
OperatingLeaseCost
439000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
34000
us-gaap Variable Lease Cost
VariableLeaseCost
12000
us-gaap Sublease Income
SubleaseIncome
73000
us-gaap Lease Cost
LeaseCost
412000
us-gaap Operating Lease Payments
OperatingLeasePayments
469000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
466000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
838000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
633000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
633000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
633000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6947000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10151000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5397000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4754000
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
135000
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
147000
CY2023Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
377000
CY2023Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
410000
CY2023Q2 us-gaap Former Gain Contingency Recognized In Current Period
FormerGainContingencyRecognizedInCurrentPeriod
4100000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-23-001633-index-headers.html Edgar Link pending
0001410578-23-001633-index.html Edgar Link pending
0001410578-23-001633.txt Edgar Link pending
0001410578-23-001633-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20230630.xsd Edgar Link pending
nwbo-20230630x10q.htm Edgar Link pending
nwbo-20230630xex21d1.htm Edgar Link pending
nwbo-20230630xex21d2.htm Edgar Link pending
nwbo-20230630xex21d2001.jpg Edgar Link pending
nwbo-20230630xex21d2002.jpg Edgar Link pending
nwbo-20230630xex21d2003.jpg Edgar Link pending
nwbo-20230630xex31d1.htm Edgar Link pending
nwbo-20230630xex32d1.htm Edgar Link pending
nwbo-20230630_cal.xml Edgar Link unprocessable
nwbo-20230630x10q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
nwbo-20230630_pre.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nwbo-20230630_def.xml Edgar Link unprocessable
nwbo-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable